Sarepta Therapeutics Dividend
Dividend criteria checks 0/6
Sarepta Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.9% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$5.71 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15
Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Sarepta: The DMD Leader
Apr 26Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments
Feb 09Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Feb 07A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Dec 06Sarepta: Revenue Keeps Rising While We Wait For Functional Data
Nov 01Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?
Nov 01Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Jul 19Sarepta Therapeutics: Faultlines May Run Deeper Than Assumed
Jun 02Most Shareholders Will Probably Agree With Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Compensation
May 27Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if SRPT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRPT's dividend payments have been increasing.
Dividend Yield vs Market
| Sarepta Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (SRPT) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Biotechs) | 2.9% |
| Analyst forecast in 3 Years (SRPT) | 0% |
Notable Dividend: Unable to evaluate SRPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SRPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate SRPT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SRPT has not reported any payouts.